Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 1 1

Status

Completed 23Active not recruiting 18Recruiting 3Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Diseases 1Thoracic Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Lung Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Intestinal Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Colonic Diseases 1

Interventions

revumenib 1repotrectinib 1Cobicistat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Has announcements × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03761108 2026-04-20

LINKER-MM1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
387 enrolled 1 FDA
Plasma cell

Multiple Myeloma, Recurrence

NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡